Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 4/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 16/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.36 |
| ▸ | KDM6B | O15054 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1219786 | 0.67 | EGLN1 (0.44) | FTOEGLN2EGLN1KDM5BKDM2A | |
| SCHEMBL21904034 | 0.65 | L3MBTL1 (0.65) | EGLN1ALDH1A1LMNA | |
| SCHEMBL29048025 | 0.64 | L3MBTL1 (0.63) | EGLN1ALDH1A1LMNA | |
| Lithium SCHEMBL30468551 | 0.64 | L3MBTL1 (0.63) | EGLN1ALDH1A1LMNA | |
| SCHEMBL28450516 | 0.63 | RAB9A (0.63) | — | |
| SCHEMBL30788089 | 0.63 | FDPS (0.43) | FTOEGLN2EGLN1ALDH1A1LMNA | |
| SCHEMBL21904003 | 0.63 | KMT2A (0.55) | FTOEGLN2EGLN1ALDH1A1LMNA | |
| SCHEMBL3683242 | 0.62 | FTO (0.59) | FTOEGLN2EGLN1KDM5BKDM2A | |
| Nicotinuric Acid SCHEMBL28292410 | 0.62 | THRB (0.73) | ALDH1A1LMNAMAPTHIF1A | |
| SCHEMBL22030672 | 0.61 | GAA (0.68) | LMNAKDM4EMAPTHIF1ASLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104427980-A | Treatment for high cholesterol | FIBROGEN INC | 2015-03-18 | — | — | CN | disclosed |
| US-20140309256-A1 | Therapeutic Method | FIBROGEN, INC | 2014-10-16 | — | — | US | disclosed |
| US-20140163061-A1 | Methods For Reducing Blood Pressure | FIBROGEN, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2013070908-A1 | THERAPEUTIC METHOD | FIBROGEN, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20110275697-A1 | REGULATION OF CYCLIN D | DANA FARBER CANCER INSTITUTE, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110039885-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS | FIBROGEN, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039879-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | FibroGen ,Inc. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039878-A1 | METHODS FOR REDUCING BLOOD PRESSURE | FIBROGEN, INC. | 2011-02-17 | — | — | US | disclosed |
| CN-101917996-A | Methods for reducing blood pressure | FIBROGEN INC | 2010-12-15 | — | — | CN | disclosed |
| EP-2250264-A2 | REGULATION OF CYCLIN D | Dana-Farber Cancer Institute, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-2231157-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENTIOR CELLS | Fibrogen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2227232-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | Fibrogen, Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| EP-2222305-A1 | METHODS FOR REDUCING BLOOD PRESSURE | Fibrogen, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100144737-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | FIBROGEN, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2010024911-A1 | METHODS FOR INCREASING NEUROGENESIS | FIBROGEN, INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| WO-2009102469-A2 | REGULATION OF CYCLIN D | DANA FARBER CANCER INSTITUTE, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009075826-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009075824-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENTIOR CELLS | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009075822-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009058403-A1 | METHODS FOR REDUCING BLOOD PRESSURE | FIBROGEN, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144737-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | NFATC1, CD4, IL2 | FTO 4088/4885EGLN2 215/4885EGLN1 238/4885 |
| US-20110039879-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | THPO, MCL1, CD14 | FTO 4102/4885EGLN2 866/4885EGLN1 1148/4885 |
| US-20110039878-A1 | METHODS FOR REDUCING BLOOD PRESSURE | HMGCR, MB, PDE3A | FTO 3686/4885EGLN2 284/4885EGLN1 1790/4885 |
| US-20110275697-A1 | REGULATION OF CYCLIN D | EGLN2, EGLN1, EGLN3 | FTO 4043/4885EGLN2 1/4885EGLN1 2/4885 |
| US-20140309256-A1 | Therapeutic Method | HIF1AN, EGLN3, EGLN2 | FTO 1807/4885EGLN2 3/4885EGLN1 6/4885 |
| US-20140163061-A1 | Methods For Reducing Blood Pressure | HMGCR, MB, PDE3A | FTO 3686/4885EGLN2 284/4885EGLN1 1790/4885 |
| US-20110039885-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS | CXCL12, SDF4, LIPG | FTO 3763/4885EGLN2 505/4885EGLN1 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.